Cynosure Taps New CEO
Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023.
Nadav Tomer is Cynosure’s new chief executive officer, effective May 1, 2023.
He succeeds Todd Tillemans, who will step down and will work closely with Mr. Tomer to ensure a smooth transition.
"Nadav has an incredibly strong track record of operational execution in the medical technology space, and we are thrilled to welcome him to Cynosure as CEO," says Sandi Peterson, Cynosure's board chairman, in a news release. "Nadav brings decades of experience helping position global med-tech businesses for strong, profitable growth by advancing innovation, accelerating global commercialization and working with research and development teams to unleash their full potential. This will be invaluable as we leverage the strength of Cynosure's talented team, global infrastructure and differentiated technology to continue bolstering the company's competitive advantage. I am confident that Nadav is the right leader to shepherd Cynosure through its next chapter."
Peterson continues, "On behalf of the entire board, I would like to thank Todd for his leadership over the past three years. He has been integral to building the strong foundation from which Cynosure is operating today, and we are grateful for his contributions. We wish Todd the best in his future endeavors."
"I am excited to join Cynosure at such an important inflection point for the medical aesthetics industry," adds Mr. Tomer. "I have been following Cynosure for some time, and I have been incredibly impressed by its innovative offerings, value proposition to its customers and world-class team. Each of these strengths is critical to long-term success and will help the company bolster the reach and performance of its global platform. Most importantly, I look forward to joining a mission-driven company that is redefining how medical aesthetics technology can empower the patients it serves to feel their best."
Mr. Tomer has held senior leadership roles for a variety of Johnson & Johnson's global businesses. In his most recent role with Johnson & Johnson, Mr. Tomer served as global president of the company's DePuy Synthes Spine franchise.
Since May 2022, Mr. Tomer has served as an operating advisor to funds affiliated with CD&R, Cynosure's lead investor. He is also an operating partner at Revival Healthcare Capital, an investment firm specializing in the medical device and diagnostic sectors of healthcare.
Mr. Tomer currently serves on the boards of directors of Augmedics and Vascular Graft Solutions. He is a graduate of the Advanced Management Program at Harvard Business School, holds a B.S. in Medicine from Ben-Gurion University of the Negev, and holds an M.B.A in Finance and New Ventures from Bar Ilan University.